BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 29775793)

  • 21. A Panel of Methylated MicroRNA Biomarkers for Identifying High-Risk Patients With Ulcerative Colitis-Associated Colorectal Cancer.
    Toiyama Y; Okugawa Y; Tanaka K; Araki T; Uchida K; Hishida A; Uchino M; Ikeuchi H; Hirota S; Kusunoki M; Boland CR; Goel A
    Gastroenterology; 2017 Dec; 153(6):1634-1646.e8. PubMed ID: 28847750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA methylation of phosphatase and actin regulator 3 detects colorectal cancer in stool and complements FIT.
    Bosch LJ; Oort FA; Neerincx M; Khalid-de Bakker CA; Terhaar sive Droste JS; Melotte V; Jonkers DM; Masclee AA; Mongera S; Grooteclaes M; Louwagie J; van Criekinge W; Coupé VM; Mulder CJ; van Engeland M; Carvalho B; Meijer GA
    Cancer Prev Res (Phila); 2012 Mar; 5(3):464-72. PubMed ID: 22135045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA methylation biomarkers for noninvasive diagnosis of colorectal cancer.
    Carmona FJ; Azuara D; Berenguer-Llergo A; Fernández AF; Biondo S; de Oca J; Rodriguez-Moranta F; Salazar R; Villanueva A; Fraga MF; Guardiola J; Capellá G; Esteller M; Moreno V
    Cancer Prev Res (Phila); 2013 Jul; 6(7):656-65. PubMed ID: 23694962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A rule for determining risk of colorectal cancer in patients with inflammatory bowel disease.
    Lutgens M; Vermeire S; Van Oijen M; Vleggaar F; Siersema P; van Assche G; Rutgeerts P; Oldenburg B;
    Clin Gastroenterol Hepatol; 2015 Jan; 13(1):148-54.e1. PubMed ID: 25041864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia.
    Ahlquist DA; Taylor WR; Mahoney DW; Zou H; Domanico M; Thibodeau SN; Boardman LA; Berger BM; Lidgard GP
    Clin Gastroenterol Hepatol; 2012 Mar; 10(3):272-7.e1. PubMed ID: 22019796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel methylation panel for the early detection of colorectal tumors in stool DNA.
    Azuara D; Rodriguez-Moranta F; de Oca J; Soriano-Izquierdo A; Mora J; Guardiola J; Biondo S; Blanco I; Peinado MA; Moreno V; Esteller M; Capellá G
    Clin Colorectal Cancer; 2010 Jul; 9(3):168-76. PubMed ID: 20643622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease.
    Shah SC; Ten Hove JR; Castaneda D; Palmela C; Mooiweer E; Colombel JF; Harpaz N; Ullman TA; van Bodegraven AA; Jansen JM; Mahmmod N; van der Meulen-de Jong AE; Ponsioen CY; van der Woude CJ; Oldenburg B; Itzkowitz SH; Torres J
    Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1106-1113.e3. PubMed ID: 29378311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of Development of More-advanced Lesions in Patients With Inflammatory Bowel Diseases and Dysplasia.
    Cremer A; Demetter P; De Vos M; Rahier JF; Baert F; Moreels T; Macken E; Louis E; Ferdinande L; Fervaille C; Dedeurwaerdere F; Bletard N; Driessen A; De Hertogh G; Vermeire S; Franchimont D;
    Clin Gastroenterol Hepatol; 2020 Jun; 18(7):1528-1536.e5. PubMed ID: 31202983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue.
    Levin TR; Corley DA; Jensen CD; Marks AR; Zhao WK; Zebrowski AM; Quinn VP; Browne LW; Taylor WR; Ahlquist DA; Lidgard GP; Berger BM
    Dig Dis Sci; 2017 Mar; 62(3):678-688. PubMed ID: 28044229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interrelations of Apoptotic and Cellular Senescence Genes Methylation in Inflammatory Bowel Disease Subtypes and Colorectal Carcinoma in Egyptians Patients.
    Salama RH; Sayed ZEA; Ashmawy AM; Elsewify WA; Ezzat GM; Mahmoud MA; Alsanory AA; Alsanory TA
    Appl Biochem Biotechnol; 2019 Sep; 189(1):330-343. PubMed ID: 30989570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inflammatory bowel disease as a risk factor for colorectal cancer.
    Lukas M
    Dig Dis; 2010; 28(4-5):619-24. PubMed ID: 21088413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of low and high-grade dysplasia in inflammatory bowel disease: the gastroenterologists' perspective and current practice in the United Kingdom.
    Thomas T; Nair P; Dronfield MW; Mayberry JF
    Eur J Gastroenterol Hepatol; 2005 Dec; 17(12):1317-24. PubMed ID: 16292084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is methylation analysis of
    Park SK; Baek HL; Yu J; Kim JY; Yang HJ; Jung YS; Choi KY; Kim H; Kim HO; Jeong KU; Chun HK; Kim K; Park DI
    Intest Res; 2017 Oct; 15(4):495-501. PubMed ID: 29142517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
    Dollinger MM; Behl S; Fleig WE
    Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methylated eyes absent 4 (EYA4) gene promotor in non-neoplastic mucosa of ulcerative colitis patients with colorectal cancer: evidence for a field effect.
    Kisiel JB; Garrity-Park MM; Taylor WR; Smyrk TC; Ahlquist DA
    Inflamm Bowel Dis; 2013 Sep; 19(10):2079-83. PubMed ID: 23867875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New Methylation Biomarker Panel for Early Diagnosis of Dysplasia or Cancer in High-Risk Inflammatory Bowel Disease Patients.
    Azuara D; Aussó S; Rodriguez-Moranta F; Guardiola J; Sanjuan X; Lobaton T; Boadas J; Piqueras M; Monfort D; Guinó E; Moreno V; Capellá G; de Oca J
    Inflamm Bowel Dis; 2018 Nov; 24(12):2555-2564. PubMed ID: 30099509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stool DNA test targeting methylated syndecan-2 (SDC2) as a noninvasive screening method for colorectal cancer.
    Su WC; Kao WY; Chang TK; Tsai HL; Huang CW; Chen YC; Li CC; Hsieh YC; Yeh HJ; Chang CC; Wang JY
    Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33393623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of Stool DNA Markers to Detect Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: A Multi-site Case-control Study.
    Itzkowitz S; Farraye FA; Limburg PJ; Gagrat Z; Olson MC; Zella J; Kisiel JB
    J Crohns Colitis; 2023 Oct; 17(9):1436-1444. PubMed ID: 37166153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased Risk of Non-conventional and Invisible Dysplasias in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease.
    Zhang R; Lauwers GY; Choi WT
    J Crohns Colitis; 2022 Dec; 16(12):1825-1834. PubMed ID: 35771958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance.
    Navaneethan U; Jegadeesan R; Gutierrez NG; Venkatesh PG; Hammel JP; Shen B; Kiran RP
    J Crohns Colitis; 2013 Dec; 7(12):e684-91. PubMed ID: 23916526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.